News

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Learn more about the in-depth topics covered in the June 2024 print issue of Dermatology Times.

Peter Prieto, MD, MPH, shares details of the IOV-COM-202 trial.

Researchers found the assessment accounted for those with moderate impact, allowing clinicians to create improved treatment plans for patients.

Dermatology Times is recapping our top expert interviews from the month of June.

Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.

A recent study found the use of CO2 lasers significantly improved patient quality of life and disease symptoms in the long-term.

Maryanne Makredes Senna, MD, shares insights into the complexities of treating alopecia areata and guidance for clinicians.

Recent research has shed light on public interest of BPO utilizing relative search volume data.

Although like count was down for posts from physicians, researchers also found an increase in share count, indicating a higher rate of reliability.

Ensemble No.2, or ENS-002, is an investigational live biotherapeutic product first detected by Concerto Biosciences using its kChip technology.

An analysis explored the feasibility of directing attention towards the thyroid receptor β as a pathway for creating novel medications to address androgenetic alopecia.

The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.

In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.

The study found that CMT is effective and well-tolerated in treating stable vitiligo, with significant positive correlations between the target area treatment ratio and repigmentation.

Researchers stated the findings highlight the need for integrated dermatological and psychological treatment approaches.

Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.

The study found a genetic link between vitiligo and autoimmune thyroid diseases, but no similar link with autoimmune hepatitis or Graves' disease.

The most significant independent predictors of adherence to dermatology follow-up appointments were younger age and previous outpatient visits.

A retrospective review found that sarecycline, a narrow-spectrum tetracycline, may be beneficial for patients with POD.

Renata Block, MMS, PA-C, and Amber Blair, MMS, PA-C, discuss the gratification of helping patients and the excitement of being on the cutting edge of research.

A recent review found the antifibrinolytic drug performed well in several clinical studies, none of which reported severe adverse events.

Patients with acne scarring who received concurrent therapy with isotretinoin and fractional radiofrequency achieved significant reductions in acne scar volume.

Keep up with the latest headlines in dermatology from the past week, including a first-of-its-kind study linking psoriasis and OCD, DermTech's Chapter 11 bankruptcy filing, and more.

In case you missed it, this week we had news about the FDA approval of sofpironium gel for primary axillary hyperhidrosis, Sun Pharma's "I LUV YA for the Long Haul" psoriasis campaign, the role of laser treatments in preventing cancer, and more.

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

Botanix Pharmaceuticals announced the approval of its sofpironium topical gel, 12.45% for adults and children ages 9 and older.

Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.

Researchers noted differences in microbial evenness, abundance composition, and functional prediction.

During the 2024 American Society of Clinical Oncology annual meeting, a poster highlighted the advantages Medicaid expansion could offer to individuals with melanoma.